Floatz logo

Fycompa

Depression

Yale UniversityPhase 2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
73/ 100

Competitive context

72 Active assets in the Depression cohort.

Asset / SponsorPhaseRating
S-Ketamine
Chinese PLA General Hospital
Phase 4BBB
Opc-34712
Dr. Albert Kar-Kin Chung
Phase 4BBB
Paroxetine
Brigham and Women's Hospital
Phase 4BBB
CITALOPRAM
Western University, Canada
Phase 4BBB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
VA Office of Research and Development
Phase 4BBB

View all 50 →

Same molecule, other indications

Fycompa is also rated in:

epilepsyDormant
BB
Indicative ·
71 / 100
View asset →
neuralgiaDormant
BB
Indicative ·
66 / 100
View asset →
epilepsyDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →